Longwood Founders Management, a Boston venture firm focused on biotech investments, announced last week that it capped its first fund at $85 million, according to a press release. The firm’s partners—Rich Aldrich, Christoph Westphal, and Michelle Dipp— previously worked together on Sirtris Pharmaceuticals, which British drug giant GlaxoSmithKline acquired for $720 million in 2008. Glaxo (NYSE:[[ticker:GSK]]) and Cambridge, MA-based biotech powerhouse Genzyme (NASDAQ:[[ticker:GENZ]]) are among the institutional investors in Longwood’s fund. The fund has already made investments in Alnara Pharmaceuticals, which Eli Lilly (NYSE:[[ticker:LLY]]) acquired in July 2010, and the biotech startup Verastem.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
